NEUROBO PHARMACEUTICALS INC (NRBO)

US64132R4048 - Common Stock

4.13  +0.15 (+3.9%)

News Image
3 days ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases,...

News Image
16 days ago - InvestorPlace

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024

NRBO stock results show that NeuroBo Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.

News Image
16 days ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third...

News Image
25 days ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases,...

News Image
2 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
2 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose...

News Image
2 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
3 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of...

News Image
3 months ago - Seeking Alpha

NeuroBo stock jumps 14% on weight-loss drug update (NASDAQ:NRBO)

NeuroBo Pharmaceuticals (NRBO) receives site approval for a Phase 1 study of obesity drug candidate DA-1726, causing shares to surge 14% in premarket trading. Read more here.

News Image
3 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
3 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
4 months ago - InvestorPlace

The Top 3 Stocks to Watch This Week

There are three stocks to watch this week as they experienced significant price movements worth your attention.

News Image
4 months ago - Seeking Alpha

NeuroBo to begin Phase 1 testing of potential Wegovy rival (NASDAQ:NRBO)

Shares of NeuroBo Pharmaceuticals (NRBO) jumped 23% in early trading Thursday after the company said it planned to begin Phase 1 testing of a weight-loss drug t

News Image
4 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
4 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
5 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases,...

News Image
5 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo to Participate in Industry and Investor Conferences in January

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
5 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...

News Image
5 months ago - Seeking Alpha

NeuroBo Pharmaceuticals announces 1-for-8 reverse stock split (NASDAQ:NRBO)

NeuroBo Pharmaceuticals announces a 1-for-8 reverse stock split, impacting the trading of its common stock on Nasdaq.

News Image
5 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases,...

News Image
5 months ago - Virtual Investor Conferences

Life Science Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

News Image
6 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo to Participate in Investor Conferences in December

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases,...

News Image
6 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

News Image
7 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

News Image
8 months ago - NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

News Image
9 months ago - NeuroBo Pharmaceuticals, Inc.

NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...